- Home
- APCX vs NERV Comparison
APCX vs NERV Comparison
Compare APCX & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APCX
- NERV
- Stock Information
- Founded
- APCX 2006
- NERV 2007
- Country
- APCX United States
- NERV United States
- Employees
- APCX N/A
- NERV N/A
- Industry
- APCX Finance: Consumer Services
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- APCX Finance
- NERV Health Care
- Exchange
- APCX Nasdaq
- NERV Nasdaq
- Market Cap
- APCX 11.7M
- NERV 10.7M
- IPO Year
- APCX N/A
- NERV 2014
- Fundamental
- Price
- APCX $0.42
- NERV $1.64
- Analyst Decision
- APCX
- NERV Hold
- Analyst Count
- APCX 0
- NERV 1
- Target Price
- APCX N/A
- NERV $5.00
- AVG Volume (30 Days)
- APCX 77.1K
- NERV 15.1K
- Earning Date
- APCX 05-13-2025
- NERV 04-30-2025
- Dividend Yield
- APCX N/A
- NERV N/A
- EPS Growth
- APCX N/A
- NERV N/A
- EPS
- APCX N/A
- NERV 0.19
- Revenue
- APCX $276,000.00
- NERV N/A
- Revenue This Year
- APCX $1,315.48
- NERV N/A
- Revenue Next Year
- APCX N/A
- NERV N/A
- P/E Ratio
- APCX N/A
- NERV $8.95
- Revenue Growth
- APCX N/A
- NERV N/A
- 52 Week Low
- APCX $0.31
- NERV $1.42
- 52 Week High
- APCX $1.49
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- APCX 57.15
- NERV 46.50
- Support Level
- APCX $0.37
- NERV $1.52
- Resistance Level
- APCX $0.45
- NERV $1.80
- Average True Range (ATR)
- APCX 0.03
- NERV 0.10
- MACD
- APCX 0.01
- NERV 0.00
- Stochastic Oscillator
- APCX 89.66
- NERV 43.30
About APCX AppTech Payments Corp.
AppTech Payments Corp is a FinTech company utilizing various payment processing and digital banking technologies to complement core merchant services capabilities. The company's patented and proprietary software will provide progressive and adaptable products that are available through a suite of synergistic offerings directly to merchants, banking institutions, and business enterprises. It is developing a secure digital payments and banking platform that powers commerce experiences for clients and customers. Based upon industry standards for payment and banking protocols, the company will offer standalone products and fully integrated solutions that deliver unparalleled payments, banking, and financial services experiences.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.